Binding and functional comparisons of two types of tumor necrosis factor antagonists
…, A Rosenberg, XY Song, D Shealy, C Wagner - … of Pharmacology and …, 2002 - ASPET
Two tumor necrosis factor (TNF) antagonists infliximab (a chimeric monoclonal antibody)
and etanercept (a p75 TNF receptor/Fc fusion protein) have been approved for treatment of …
and etanercept (a p75 TNF receptor/Fc fusion protein) have been approved for treatment of …
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
SB Hanauer, CL Wagner, M Bala, L Mayer… - Clinical …, 2004 - Elsevier
Background & Aims : The effect of different treatment regimens on antibody responses to
infliximab and their clinical significance was examined by using data from ACCENT I. Methods : …
infliximab and their clinical significance was examined by using data from ACCENT I. Methods : …
Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets
CL Wagner, MA Mascelli, DS Neblock, HF Weisman… - 1996 - ashpublications.org
A large number of glycoprotein (GP) IIb/IIIa receptors are present on the surface of platelets.
Studies to define precisely the number of GPIIb/IIIa receptors using specific monoclonal …
Studies to define precisely the number of GPIIb/IIIa receptors using specific monoclonal …
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double‐blind …
EW St. Clair, CL Wagner… - … : Official Journal of …, 2002 - Wiley Online Library
Objective To investigate the relationship between serum concentrations of infliximab, a
monoclonal anti–tumor necrosis factor α antibody, and clinical improvement from infliximab …
monoclonal anti–tumor necrosis factor α antibody, and clinical improvement from infliximab …
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double‐blind, placebo‐controlled, dose‐ranging study
…, S Hall, EC Hsia, J Han, C Wagner… - Arthritis & …, 2008 - Wiley Online Library
Objective To assess the efficacy, safety, and pharmacology of subcutaneous administration
of golimumab in patients with active rheumatoid arthritis (RA) despite treatment with …
of golimumab in patients with active rheumatoid arthritis (RA) despite treatment with …
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2 …
Background Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23
and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. …
and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. …
Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
MA Mascelli, ET Lance, L Damaraju, CL Wagner… - Circulation, 1998 - Am Heart Assoc
Background—The glycoprotein (GP) IIb/IIIa receptor antagonist abciximab is approved for use
in high-risk percutaneous coronary interventions. The purpose of the present study was to …
in high-risk percutaneous coronary interventions. The purpose of the present study was to …
Scientific and regulatory considerations on the immunogenicity of biologics
G Shankar, E Shores, C Wagner, A Mire-Sluis - Trends in biotechnology, 2006 - cell.com
Immune responses against non-vaccine biologics can affect their efficacy and safety, resulting
in adverse events that could include administration reactions, hypersensitivity, deficiency …
in adverse events that could include administration reactions, hypersensitivity, deficiency …
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys
…, K Geboes, SD Rousselle, CL Wagner - … of Pharmacology and …, 2005 - ASPET
Infliximab (IFX) is a chimeric IgG1 monoclonal antibody specific for human tumor necrosis
factor-α that is approved in the United States and Europe for the treatment of rheumatoid …
factor-α that is approved in the United States and Europe for the treatment of rheumatoid …
Immunogenicity of therapeutic monoclonal antibodies.
C Pendley, A Schantz, C Wagner - Current opinion in molecular …, 2003 - europepmc.org
There are currently 13 monoclonal antibodies or antibody constructs approved for therapeutic
use in the US and at least another 400 products are in clinical testing or undergoing …
use in the US and at least another 400 products are in clinical testing or undergoing …